

Brooklyn Methodist Hospital, Brooklyn, NY, USA, ²Nationwide Children's Hospital, Columbus, OH, USA

BACKGROUND: Patients with relapsed CNS NGGCTs experience poor outcomes. Our aim to explore prognostic factors that may guide future clinical trials. **METHODS:** A review of clinical trials that included patients with relapsed CNS NGGCTs was performed. **RESULTS:** Seventy-four patients were identified; only 14 patients (19%) were long-term survivors. Patients who relapsed >24 months after initial diagnosis had a survival rate of 47% compared with 15% of patients who relapsed in <24 months after initial diagnosis ($p=0.015$). Patient with serum/cerebrospinal fluid (CSF) alpha-fetoprotein (AFP) level <25 ng/ml at relapse had a survival rate of 40% compared with 0% among patients with serum/CSF AFP level >25 ng/ml at relapse ($p=0.0015$). Patients who achieved complete response/continued complete response (CR/CCR) by the end of therapy had a survival rate of 59% compared with 3% among patients who had less than CR/CCR by the end of therapy ($p=0.0001$). Patients who received marrow-ablative chemotherapy followed by autologous hematopoietic cell rescue (HDCx/AuHCR) at relapse had a survival rate of 33% compared with 9% of patients who did not receive HDCx/AuHCR at relapse ($p=0.056$). The extent of surgical resection, receiving radiotherapy, and beta-human chorionic gonadotropin levels at relapse were not statistically associated with improved outcomes. **CONCLUSION:** Timing of relapse (>24 months after initial diagnosis), serum/CSF AFP <25 ng/ml at relapse, achieving CR/CCR after treatment were associated with a positive impact on survival. Receiving HDCx/AuHCR at relapse was associated with an improved outcome trend among the patients.

GCT-41. RESPONSE-BASED RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED CENTRAL NERVOUS SYSTEM LOCALIZED GERMINOMA: A CHILDREN'S ONCOLOGY GROUP (COG) PROSPECTIVE PHASE 2 CLINICAL TRIAL

Ute Bartels¹, Jason Fangusaro², Dennis Shaw³, Aashim Bhatia⁴, Arzu Omar-Thomas⁵, Shengjie Wu⁵, Shannon MacDonald⁶, Erin Murphy⁷, Mark Souweidane⁸, Maryam Fouladi⁹, Amar Gajjar⁵, Girish Dhall¹⁰, and Soumen Khatua¹¹; ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Aflac Cancer Center, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, USA, ³Seattle Children's Hospital, Seattle, WA, USA, ⁴Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA, ⁵St. Jude Children's Research Hospital, Memphis, TN, USA, ⁶Massachusetts General Hospital, Boston, MA, USA, ⁷Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA, ⁸Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center, New York, NY, USA, ⁹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA, ¹⁰The Alabama Center for Childhood Cancer and Blood Disorders at Children's of Alabama, Alabama, AL, USA, ¹¹MD Anderson Cancer Center, Houston, TX, USA

BACKGROUND: The objective of stratum 2 of COG ACNS1123 was to evaluate children and young adults (3–21 years) with localized central nervous system (CNS) germinoma and investigate whether simplified pre-irradiation chemotherapy followed by response based dose-reduced whole ventricular irradiation (WVI) would maintain a high progression-free survival (PFS) while reducing long term treatment burden. **METHODS:** Pre-irradiation chemotherapy consisted of 4 cycles of carboplatin and etoposide every 21 days followed by response-based irradiation (XRT). Patients with a complete response (CR) to pre-XRT chemotherapy received 18Gy WVI + 12Gy boost to the tumor bed. Patients with partial response (PR) but less than 1.5 cm residual proceeded to 24Gy WVI + 12Gy boost. All patients were also enrolled on COG ALTE07C1 to prospectively evaluate and longitudinally model the cognitive, social and behavioral functioning. **RESULTS:** During a total accrual time of 45.5 months from 05/2012 to 06/2018, 137 eligible patients were enrolled. Median age was 14.09 years (4.95–21.46), 73% were male, and 45.26% had elevated β hCG in serum and/or cerebrospinal fluid. Twenty-nine patients (21.17%) did not have tissue biopsy. Eleven patients underwent second-look surgery; 7 had mature teratoma and 4 had non-viable tumor. Eighty-one patients (59.13%) had a CR. There were 4 relapses in patients receiving 18Gy WVI + boost, but no deaths. No unexpected treatment-related events were observed. The estimated 3-year PFS was 94.4 \pm 2.7% among 74 evaluable subjects. **CONCLUSION:** This study shows promise in XRT reduction for patients with localized CNS germinoma and CR. Long-term survival outcomes and ALTE07C1 data are being evaluated.

GCT-42. CLINICAL CHARACTERISTICS OF LOCALIZED CENTRAL NERVOUS SYSTEM NON-GERMINOMATOUS GERM CELL TUMORS (NGGCT) PATIENTS ENROLLED ON ACNS1123 WITH RELAPSE: A CHILDREN'S ONCOLOGY GROUP (COG) STUDY
Girish Dhall¹, Shengjie Wu², Arzu Onar-Thomas², Dennis Shaw³, Shannon MacDonald⁴, Erin Murphy⁵, Soumen Khatua⁶, Ute Bartels⁷, and Jason Fangusaro⁸; ¹University of Alabama at Birmingham, Birmingham, AL, USA, ²St. Jude Children's Research Hospital, Memphis, TN, USA,

³Seattle Children's Hospital, Seattle, WA, USA, ⁴Massachusetts General Hospital, Boston, MA, USA, ⁵Cleveland Clinic, Cleveland, OH, USA, ⁶M.D. Anderson Cancer Center, Houston, TX, USA, ⁷Hospital for Sick Children, Toronto, ON, Canada, ⁸Emory University, Atlanta, GA, USA

ACNS1123 was a Children's Oncology Group Phase 2 study that was undertaken to determine whether irradiation could be safely reduced without impacting survival in a subgroup of NGGCT patients. Between May 2012-Jan 2017, 107 eligible patients were accrued to Stratum 1 (NGGCT stratum). Sixty-six (61.7%) patients achieved a complete/partial response (CR/PR) to induction chemotherapy and received 30.6Gy whole ventricular field irradiation followed by 54Gy tumor-bed boost achieving a 2-year progression-free survival rate of 89% (95% CI:81%-97%) and overall survival rate of 92% (95% CI:86%-99%). Eight patients progressed; 6 had a spinal relapse and 2 patients had a local plus spinal relapse. Seven of eight patients had marker elevation at relapse and data was not available in one patient. At diagnosis, location was pineal in six cases, suprasellar in one, and bifocal in one case. Four patients had beta HCG β and AFP elevation and two each had HCG β and AFP elevation alone at diagnosis. Only two patients had HCG β or AFP >1000 (HCG β 3550 in one patient and AFP of 1340 in another). All eight patients were CR by markers; four had radiographic CR and four had a PR. Five patients had surgery at diagnosis: two had embryonal carcinoma, one germinoma, and two mixed germ cell tumor with malignant elements on histology. A consistent significant risk factor could not be identified to explain excess of spinal failures seen in our cohort.

GCT-43. GAIN OF SHORT ARM OF CHROMOSOME 12 IS A MOLECULAR MARKER TO PREDICT PROGNOSIS AND REPRESENTS AN EARLY EVENT IN TUMORIGENESIS IN INTRACRANIAL GERM CELL TUMORS

Kaishi Satomi^{1,2}, Hirokazu Takami^{2,3}, Shintaro Fukushima², Yoichi Nakazato⁴, Shota Tanaka³, Nobuhito Saito³, Masayuki Kanamori⁵, Toshihiro Kumabe⁵, Keiichi Kobayashi⁶, Motoo Nagane⁶, Toshihiko Iuchi⁷, Koji Yoshimoto⁸, Masahiro Mizoguchi⁸, Kaoru Tamura⁹, Taketoshi Maehara⁹, Keiichi Sakai¹⁰, Kazuhiko Sugiyama¹¹, Kiyotaka Yokogami¹², Hideo Takeshima¹², Masahiro Nonaka¹³, Akio Asai¹³, Ryo Nishikawa¹⁴, Masao Matsutani¹⁵, and Koichi Ichimura²; ¹Department of Diagnostic Pathology, National Cancer Center Hospital, Chuo, Tokyo, Japan, ²Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Chuo, Tokyo, Japan, ³Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Bunkyo, Tokyo, Japan, ⁴Department of Pathology, Hidaka Hospital, Takasaki, Gumma, Japan, ⁵Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan, ⁶Department of Neurosurgery, Kyorin University Faculty of Medicine, Mitaka, Tokyo, Japan, ⁷Department of Neurosurgery, Chiba Cancer Center, Chiba, Chiba, Japan, ⁸Department of Neurosurgery, Graduate School of Medical Sciences Kyusyu University, Fukuoka, Fukuoka, Japan, ⁹Department of Functional Neurosurgery, Tokyo Medical and Dental University, Bunkyo, Tokyo, Japan, ¹⁰Department of Neurosurgery, Shinshu Ueda Medical Center, Ueda, Nagano, Japan, ¹¹Department of Clinical Oncology and Neuro-oncology Program, Cancer Treatment Center, Hiroshima University Hospital, Hiroshima, Hiroshima, Japan, ¹²Department of Neurosurgery, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki, Japan, ¹³Department of Neurosurgery, Kansai Medical University Hospital, Hirakata, Osaka, Japan, ¹⁴Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan, ¹⁵Gotanda Rehabilitation Hospital, Shinagawa, Tokyo, Japan

Gain of short arm of chromosome 12 (12p) is commonly observed in testicular germ cell tumors (tGCTs) and also seen in intracranial GCTs (iGCTs). However, little is known about the clinical significance of 12p gain in iGCTs. We have collected over 200 fresh frozen tissue samples of iGCTs through the Intracranial Germ Cell Tumor Genome Analysis Consortium in Japan. Firstly, we analyzed DNA methylation profile in 83 iGCTs, 3 tGCTs (seminomas) and 6 normal control samples using Infinium Human Methylation 450K BeadChip array (Illumina, CA, USA) in order to determine 12p gain status. Then, fluorescence in situ hybridization (FISH) study was carried out on 3 mixed iGCT cases using 12p/CEP12 probe (Abbott Molecular, Abbott park, IL, USA). Lastly, 58 iGCTs with clinicopathological information were analyzed for progression-free survival (PFS) and overall survival (OS). Gain of 12p was observed in 100% (3/3) of seminoma, 14% (3/22) of germinoma, 17% (1/6) of mature teratoma, 25% (1/4) of immature teratoma, 55% (11/20) of mixed germ cell tumor, 100% (4/4) of yolk sac tumor, 100% (1/1) of embryonal carcinoma, and 100% (1/1) of choriocarcinoma. In total, 45% (37/83) of iGCT showed 12p gain. Different histological components in each mixed GCT shared the same 12p copy number status within each mixed GCT case. Both PFS and OS were significantly worse in iGCTs with 12p gain (PFS: $P=0.027$, OS: $P=0.0012$). Gain of 12p can be a molecular marker to predict prognosis and represents an early event in tumorigenesis prior to histological differentiation in iGCTs.